JPMorgan Downgrades Audentes Therapeutics (BOLD) to Neutral Following Acquisition
Tweet Send to a Friend
JPMorgan analyst Anupam Rama downgraded Audentes Therapeutics (NASDAQ: BOLD) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
